VERAXA Biotech AG (NASDAQ: VRXA) has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies. The collaboration represents an important milestone in preparing the company’s most advanced oncology candidate for clinical development.
ATUM will apply its proprietary Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate. This technology is designed to improve the efficiency and stability of cell line generation, which is critical for producing consistent and scalable batches of the therapeutic protein for nonclinical studies and eventual clinical trials.
The partnership supports manufacturing, analytical development, and nonclinical studies required before clinical testing. VERAXA’s BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. By engineering T-cell engagers to more precisely target tumor cells while sparing healthy tissues, the platform aims to address a key limitation of current immunotherapies.
VERAXA recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development. This expansion reflects the company’s commitment to advancing its pipeline of novel cancer therapies.
The selection of ATUM follows VERAXA’s broader strategy to leverage external expertise for key manufacturing steps, allowing the company to focus on its core competency of designing innovative cancer treatments. The Leap-In Transposase(R) technology is expected to expedite the generation of high-producing cell lines, reducing timelines and costs associated with early-stage development.
VERAXA Biotech is an emerging leader in designing novel cancer therapies, with its BiTAC(R) platform at the forefront. The company’s lead BiTAC-TCE program targets a solid tumor indication, and successful completion of cell line development will enable the initiation of IND/CTA-enabling studies. These studies are essential for filing an Investigational New Drug application with the FDA or a Clinical Trial Application with European regulators.
Investors interested in VERAXA’s progress can access the latest news and updates in the company’s newsroom at https://ibn.fm/VRXA.
